Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Joshua Bauml, MD, moves to The Janssen Pharmaceutical Companies of Johnson & Johnson

By

Estimated Read Time:

1 minute

Names & News

Joshua Bauml, MD, has moved to The Janssen Pharmaceutical Companies of Johnson & Johnson from the University of Pennsylvania. Dr. Bauml was with the University of Pennsylvania for a decade—2 years as a fellow and 8 years as faculty—most recently servicing as an Assistant Professor of Medicine. Dr. Bauml will be joining the lung cancer therapies team at Janssen as Executive Medical Director, and will be working on drug development.


About the Authors